insights_auto
Why is GRAL down 8.88%?
Dive Deeperchevron_right
GRAL:NASDAQ
Grail Inc
$105.60
arrow_downward
-8.88%(-10.29) 1D
$108.11
arrow_upward
+2.38% (+2.51)todayPre-market
Closed: Nov 16, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$111.41
High
$113.06
Low
$104.65
Mkt. cap
4.75B
Avg. vol.
952.19K
Volume
3.05K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.50
Shares outstanding
44.96M
No. of employees
910
Open
$111.41
High
$113.06
Low
$104.65
Mkt. cap
4.75B
Avg. vol.
952.19K
Volume
3.05K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.50
Shares outstanding
44.96M
No. of employees
910
News stories
From web sources and news partners
GuruFocus
·
6 hours ago
GRAIL Inc (GRAL) CFO Aaron Freidin Sells 3,000 Shares
Investing.com
·
8 hours ago
GRAIL CFO Aaron Freidin sells $322,866 in common stock
Investing.com Canada
·
8 hours ago
Form 4 Grail Inc: Aaron Freidin (CFO) For: 16 November By Investing.com
Investor's Business Daily
·
1 month ago
This Stock, Up Almost 70%, May Have Found Cancer's Holy 'Grail'
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorHealth Care
IndustryBiotechnology
Websitegrail.com